4//SEC Filing
SCHADE CHRISTIAN S 4
Accession 0001140361-21-006730
CIK 0001781983other
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 7:05 PM ET
Size
14.8 KB
Accession
0001140361-21-006730
Insider Transaction Report
Form 4
SCHADE CHRISTIAN S
DirectorPresident & CEO
Transactions
- Award
Stock Option (right to Buy)
2021-02-25+329,000→ 329,000 totalExercise: $6.00Exp: 2031-02-25→ Common Stock (329,000 underlying) - Award
Common Stock
2021-02-25+88,500→ 176,660 total - Award
Common Stock
2021-02-25+77,000→ 77,160 total
Holdings
- 1,000(indirect: By Children)
Common Stock
- 1,000(indirect: By Children)
Common Stock
- 1,000(indirect: By Children)
Common Stock
- 1,000(indirect: By Children)
Common Stock
- 1,000(indirect: By Children)
Common Stock
- 1,000(indirect: By Children)
Common Stock
- 5,000(indirect: By Spouse)
Common Stock
Footnotes (4)
- [F1]These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 25,666 shares on February 25, 2022, (ii) 25,667 shares on February 25, 2023 and (iii) 25,667 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
- [F2]These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 29,500 shares on August 25, 2021, (ii) 29,500 shares on February 25, 2022 and (iii) 29,500 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
- [F3]Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.
- [F4]The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
Documents
Issuer
Aprea Therapeutics, Inc.
CIK 0001781983
Entity typeother
Related Parties
1- filerCIK 0001214496
Filing Metadata
- Form type
- 4
- Filed
- Feb 28, 7:00 PM ET
- Accepted
- Mar 1, 7:05 PM ET
- Size
- 14.8 KB